Lafayette, Louisiana – Baum, Hedlund, Aristei & Goldman has filed a federal Actos bladder cancer bundled complaint on behalf of 20 plaintiffs against drug giant Takeda Pharmaceuticals, its subsidiaries and Eli Lilly, which launched Actos along with Takeda in 1999. These personal injury claims allege that the Type 2 diabetes drug Actos caused bladder cancer.
The complaint alleges that defendants were aware of a link between Actos (pioglitazone) and bladder cancer for over a decade, and yet continued to promote the drug as if it were safe and effective. Furthermore, Takeda and the other defendants in this case willfully and wantonly misled the plaintiffs, the health care community, and patients using Actos around the world.
Baum Hedlund Lawyers Appointed to Actos Plaintiffs Steering Committee Tuesday, November 13, 2012
Senior Baum Hedlund partner, Michael Baum, and partner Cynthia Garber, have recently been appointed to the Plaintiffs' Steering Committee (PSC), Judicial Council Coordinated Proceedings (JCCP 4696) In re Actos Product Liability Cases in Los Angeles, California. The members of the PSC manage the complex mass tort litigation arising from the Actos bladder cancer cases that have been consolidated in California at Los Angeles Superior Court.
Actos Bladder Cancer Risk Should be Center Stage During American Diabetes Month Monday, November 5, 2012
November is American Diabetes Month. In an effort to keep diabetes patients safe from unnecessary risks to their health, the law firm of Baum, Hedlund, Aristei & Goldman wants to raise awareness about the dangers associated with Actos (pioglitazone), a drug used to treat Type 2 diabetes.
An ongoing epidemiological study conducted by Actos manufacturer Takeda Pharmaceuticals indicates that taking the drug can increase the risk of developing bladder cancer by 40 percent. The results of another study conducted by the French government, prompted France and Germany to pull Actos off the shelves, citing the link to bladder cancer. Canada has taken similar steps to remove the drug from the country's list of approved medications.
Fourteen Diabetes Patients Sue Takeda and Eli Lilly in California
for Actos-Induced Bladder Cancer Thursday, October 11, 2012
Baum Hedlund Aristei & Goldman has filed a personal injury lawsuit on behalf of 14 people who claim they developed bladder cancer after taking the Type-2 diabetes drug Actos (pioglitazone). The lawsuit, case number BC-492184, filed as a bundled complaint, was filed in Los Angeles Superior Court against Actos manufacturer Takeda Pharmaceuticals, its subsidiaries and Eli Lilly (which collaborated with Takeda in the launch and marketing of Actos).
According to the complaint, Takeda failed to properly design, test, manufacture and market Actos. Takeda knew or should have known that Actos use carried a significant risk of bladder cancer but did not adequately warn the American public about this life-threatening Actos side effect, the complaint alleges.
According to Baum Hedlund, the bundled complaint (case no. BC-492185) joins 115 other cases already filed in the Judicial Council Coordinated Proceedings (JCCP 4696 - In re Actos Product Liability Cases coordinated proceeding) at Los Angeles Superior Court.
The suit claims that use of the type-2 diabetes drug caused bladder cancer, pain and suffering, mental anguish, economic loss, diminished enjoyment of life, bodily impairments and eventually death.
Actos Bladder Cancer Lawsuits Reach One Thousand Mark in Louisiana Federal Court Monday, October 1, 2012
Lafayette, Louisiana, October 1, 2012 – The families of two men who died of bladder cancer have filed a federal Actos bladder cancer lawsuit against the manufacturers of the diabetes medication. The law firm of Baum Hedlund Aristei & Goldman is representing the families of James Person of Georgia and Pablo Astorga of California, who died of bladder cancer after taking Actos. The families are suing Takeda Pharmaceuticals, its subsidiaries, and drugmaker Eli Lilly (Actos was jointly launched by Takeda and Eli Lilly in 1999).
This lawsuit (case no. 6:12-cv-02446) will join a thousand similar Actos wrongful death and personal injury claims which have been transferred to the Actos MDL, In Re: Actos (Pioglitazone) Products Liability Litigation, 6:11-md-2299, and consolidated in the United States District Court for the Western District of Louisiana before U.S. District Judge Rebecca Doherty.
Nearly 800 Actos Bladder Cancer Cases Have Been Consolidated in Federal Court
with Four More Filed Last Week by Baum Hedlund Tuesday, August 21, 2012
Baum, Hedlund, Aristei & Goldman reports that almost 800 federal cases have been filed by individuals who allege that Actos caused their bladder cancer. The law firm also announced that it just filed a new bundled complaint (6:12-cv-02208) in federal court against Takeda Pharmaceuticals, its subsidiaries and Eli Lilly on behalf of four men who claim that taking the diabetes drug Actos (pioglitazone), caused their bladder cancer. Two of the men are joined by their wives in the Actos bladder cancer case.
The complaint, which was filed last week in the United States District Court in the District of Louisiana in Lafayette, alleges that defendants willfully misled plaintiffs, the health care community and the general public by aggressively marketing Actos as safe when they knew or should have known that the diabetes medication was linked to bladder cancer. The personal injury case seeks compensatory damages from Takeda, its subsidiaries and Eli Lilly (which launched and marketed Actos in the U.S. along with a Takeda subsidiary) for the pain and suffering Actos caused the four men.
Takeda Willfully Misled Public about Bladder Cancer Risk, New Actos Lawsuit Alleges Wednesday, August 15, 2012
Twelve people have filed a personal injury Actos lawsuit against manufacturer Takeda Pharmaceuticals and subsidiaries, as well as Eli Lilly (which collaborated with Takeda Limited to promote and market Actos in the U.S.). The lawsuit was filed by the national law firm of Baum, Hedlund, Aristei & Goldman, P.C. on behalf of the Plaintiffs, who claim that the Type II Diabetes medication Actos (pioglitazone) caused their bladder cancer. Five of the seven plaintiffs with bladder cancer are also joined by their spouses.
Defendants Takeda, its subsidiaries and Eli Lilly face allegations that the companies have been aware of the association between Actos and bladder cancer for over a decade, and willfully concealed this knowledge from Plaintiffs, the health care community and the general public.
Takeda Stock in Falling as Actos Sales Continue to Plummet Monday, July 09, 2012
After reviewing data from an ongoing epidemiological study, the Food and Drug Administration (FDA) warned of a link between the use of Actos (pioglitazone) and the development of bladder cancer. According to the agency, patients who have used the diabetes medication for a long time, or have been taking accumulated dosages, are at risk of developing bladder cancer. If you are suffering from bladder cancer and have been a long-time Actos user, you may be entitled to compensation and should consider joining an Actos lawsuit.
Was Your Bladder Cancer the Result of Actos Use? Friday, June 01, 2012
After reviewing data from an ongoing epidemiological study, the Food and Drug Administration (FDA) warned of a link between the use of Actos (pioglitazone) and the development of bladder cancer. According to the agency, patients who have used the diabetes medication for a long time, or have been taking accumulated dosages, are at risk of developing bladder cancer. If you are suffering from bladder cancer and have been a long-time Actos user, you may be entitled to compensation and should consider joining an Actos lawsuit.
New Study: Actos Users 80 Percent More Likely to Develop Bladder Cancer Thursday, May 31, 2012
According to data released by the Food and Drug Administration (FDA) in August, diabetes patients who have been using Actos over a long period or have been taking cumulative dosages of the drug need to be alert to the symptoms of bladder cancer.
European Medicines Agency Recommends New Warnings
for Actos Bladder Cancer Risk Thursday, April 19, 2012
In finalizing their review of the diabetes drug pioglitazone, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) maintains that there is a risk of bladder cancer for patients taking pioglitazone-containing drugs like Actos.
New York – Actos Bladder Cancer Information Tuesday, April 17, 2012
Diabetes patients living in New York and taking Actos, should be made aware that in June 2011, results from a French epidemiological study revealed that use of the diabetes drug Actos (pioglitazone) led to a higher risk of developing bladder cancer.
Texas - Actos Bladder Cancer Information Friday, April 13, 2012
This is an alert to diabetes patients in Texas that Pioglitazone, the main ingredient in the diabetes drug Actos, has been linked to a 40 percent increased risk of developing bladder cancer.
Florida Actos Bladder Cancer Information Monday, April 02, 2012
If you live in Florida and are taking the diabetes medication Actos, please be aware that the Food and Drug Administration has warned of a link between the diabetes drug Actos and bladder cancer. According to the agency, cumulative doses and long-term use of Takeda Pharmaceutical’s popular diabetes drug Actos (pioglitazone) has been linked with a significantly higher risk of developing the deadly form of cancer.
California - Actos Bladder Cancer Information Thursday, March 29, 2012
California residents should be made aware that Takeda Pharmaceutical’s popular diabetes drug Actos (pioglitazone) has been the center of controversy since scientific data connected Actos use with a higher risk of bladder cancer.
Baum Hedlund Files Federal Actos Bladder Cancer Lawsuit
On Behalf Of Virginia Couple Monday, March 26, 2012
Baum Hedlund Aristei & Goldman has filed Actos bladder cancer lawsuits in Superior Court for the State of California for the County of Los Angeles against Japanese-based Takeda Pharmaceuticals and its subsidiaries on behalf of three California residents and their spouses alleging Actos caused their bladder cancer.
Actos Manufacturer Evaded Reporting Actos Bladder Cancers and Congestive Heart Failures, According to Former Takeda Medical Reviewer Tuesday, March 20, 2012
Manufacturer of Actos Sees Sharp Drop in Sales of the Drug Wednesday, January 25, 2012
Takeda Pharmaceuticals, Japan’s largest pharmaceutical company and manufacturer of the diabetes drug Actos (pioglitazone), is reportedly cutting its global workforce by as much as 9% between now and 2015.
Actos Manufacturers Failed to Disclose a Risk of Bladder Cancer Wednesday, January 11, 2012
The Law Journal reports that hundreds of Actos bladder cancer are being consolidated in Louisiana, Illinois and California. Some 125 lawsuits were coordinated in federal court On Dec. 29, by the U.S. Judicial Council on Multidistrict Litigation and will be heard in Louisiana.
Actos Plaintiffs Attorneys Vow to Keep California Bladder Cancer Cases in State Court Friday, January 06, 2012
On January 4, 2012, a hearing was held in the Central Civil West Courthouse, Los Angeles Superior Court to hear a Petition to coordinate and consolidate all Actos bladder cancer cases filed in California state courts (JCCP4696). The Honorable Carl J. West was appointed by the California Judicial Council as the Coordination Motion Judge.
Servicios también disponibles en Español | Nous sommes fières d’offrir nos services en Français | 한국어로도 서비스를 제공해 드립니다.
Legal Advertisement | This is Not a Medical Website | Site Disclaimers | Privacy Policy
Martindale-Hubbell is the facilitator of a peer review rating process. Ratings reflect the confidential opinions of members of the Bar and the Judiciary.
Martindale-Hubbell Ratings fall into two categories - legal ability and general ethical standards. AV® Preeminent ™ is a certification mark of Reed Elsevier Properties Inc.,
used in accordance with the Martindale-Hubbell certification procedures, standards and policies.
The cases represented on this site or our past performance, verdicts, settlements, testimonials or endorsements do not constitute a guarantee, warranty,
or prediction regarding the outcome of future cases.
